tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

CytoMed Therapeutics Launches ATM Offering Program to Boost Growth

Story Highlights
CytoMed Therapeutics Launches ATM Offering Program to Boost Growth

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

CytoMed Therapeutics Limited ( (GDTC) ) has provided an announcement.

On August 18, 2025, CytoMed Therapeutics Limited announced the initiation of an At-the-Market (ATM) offering program through a sales agreement with R.F. Lafferty & Co., Inc. This agreement allows CytoMed to sell ordinary shares worth up to $4,304,945, with the proceeds intended for general corporate purposes, including business diversification, development initiatives, and potential acquisitions. The announcement highlights the company’s strategic move to enhance its financial flexibility and explore growth opportunities, potentially impacting its market positioning and stakeholder interests.

Spark’s Take on GDTC Stock

According to Spark, TipRanks’ AI Analyst, GDTC is a Neutral.

CytoMed Therapeutics Limited is facing significant financial challenges, with substantial declines in revenue and persistent losses. The technical indicators suggest a bearish trend with potential short-term opportunities due to oversold conditions. Valuation metrics, including a negative P/E ratio, reflect poor profitability and lack of dividend yield. These factors contribute to a low overall stock score, highlighting the need for improved financial strategies and market conditions to enhance investor confidence.

To see Spark’s full report on GDTC stock, click here.

More about CytoMed Therapeutics Limited

CytoMed Therapeutics Limited is a Singapore-based clinical stage biopharmaceutical company that was incorporated in 2018. It focuses on developing novel cell-based allogeneic immunotherapies for the treatment of various human cancers, utilizing proprietary technologies such as gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell. The company was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore’s leading research and development agency.

Average Trading Volume: 11,783

Technical Sentiment Signal: Sell

Current Market Cap: $22.59M

See more data about GDTC stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1